search
pharmaceutical industry
Trends
- 1EU Council adopts overhaul of pharmaceutical rules▼‘Pharma package’: Council adopts new rules for a fairer and more competitive EU pharmaceutical sector
The Council of the European Union has adopted the 'pharma package', a set of new rules intended to make the EU pharmaceutical sector fairer and more competitive. The reform updates how medicines are authorised, priced and supplied across the bloc, aiming to speed up patient access to treatments and address shortages while balancing incentives for drug developers.
- 2European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.
- 3Weight-loss jab maker's Vogue World sponsorship sparks concern▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, the maker of weight-loss injection Wegovy, is sponsoring Vogue World, and the partnership is drawing criticism from commentators who call it problematic. Critics argue that having a pharmaceutical weight-loss brand fund a major fashion event risks glamorising slimming jabs and reinforcing harmful body-image pressures in an industry already criticised for promoting thinness.
- 4WSJ warns U.S. tariffs are hurting American biotech●The U.S. Tariff Attack on U.S. Biotech https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92?mod=rss
The Wall Street Journal's opinion section argues that U.S. tariff policy is damaging the domestic biotechnology industry, which the piece frames as an ironic case of Washington's trade measures attacking American companies. The article is being shared in economic and policy discussions, drawing attention to the tension between protectionist trade policy and the administration's stated goal of strengthening U.S. industrial and pharmaceutical sectors.
- 5
A new EU report warns that pharmaceutical rules under debate in Brussels could make it harder for patients to access medicines. Concerns centre on provisions said to affect availability of treatments across member states, with patient groups and industry watching closely as the EU's pharmaceutical legislation reform moves forward.
- 6
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 7Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.